Flags are seen outside Novo Nordisk headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS/Jacob Gronholt-Pedersen/File Photo
COPENHAGEN, March 3 (Reuters) – Danish drugmaker Novo Nordisk has more than doubled its target for sales of obesity drugs by 2025 after overwhelming demand for its new Wegovy drug.
Novo Nordisk now aims to generate annual obesity drug sales of more than 25 billion Danish crowns ($3.72 billion) by 2025, the company said at its capital markets day on Thursday.
Its previous goal was to double its 2019 obesity drug sales totalling 5.7 billion crowns.
The company had a breakthrough with Wegovy, which was released in the United States in June last year and helps to achieve weight loss of 17% on average over almost two years.
Novo Nordisk was overwhelmed by initial demand for Wegovy, leading to supply shortages.
The company took a further hit in December, when a contract manufacturer filling syringes for pens to inject the drug temporarily halted deliveries and manufacturing after issues relating to good manufacturing practice.
Novo expects to be able to meet demand in the second half of this year.
($1 = 6.7157 Danish crowns)
Our Standards: The Thomson Reuters Trust Principles.
Sign up to our health newsletter to keep up with the latest healthcare trends and pharmaceutical news.
Subscribe to our newsletter to get all the news you need to start your day.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved